Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $39 | $50 | $48 | $44 |
| % Growth | -21.7% | 2.7% | 10.2% | – |
| Cost of Goods Sold | $13 | $15 | $12 | $10 |
| Gross Profit | $26 | $35 | $36 | $34 |
| % Margin | 67% | 70.1% | 75.1% | 78.1% |
| R&D Expenses | $69 | $53 | $71 | $76 |
| G&A Expenses | $45 | $43 | $49 | $57 |
| SG&A Expenses | $45 | $43 | $49 | $57 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $4 | $5 | $4 |
| Operating Expenses | $116 | $100 | $125 | $138 |
| Operating Income | -$90 | -$66 | -$89 | -$104 |
| % Margin | -231.8% | -132.1% | -184.1% | -236.3% |
| Other Income/Exp. Net | $9 | $5 | -$2 | -$4 |
| Pre-Tax Income | -$81 | -$61 | -$91 | -$108 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$81 | -$60 | -$91 | -$108 |
| % Margin | -207.9% | -121.6% | -188.2% | -245.2% |
| EPS | -1.45 | -1.1 | -1.68 | -2.07 |
| % Growth | -31.8% | 34.5% | 18.8% | – |
| EPS Diluted | -1.45 | -1.1 | -1.68 | -2.07 |
| Weighted Avg Shares Out | 56 | 55 | 54 | 52 |
| Weighted Avg Shares Out Dil | 56 | 55 | 54 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $6 | $6 | $7 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $14 | $16 | $15 | $16 |
| EBITDA | -$67 | -$46 | -$68 | -$143 |
| % Margin | -171.4% | -92.9% | -141.4% | -327.2% |